Waldenström Macroglobulinemia, An Issue of Hematology/Oncology Clinics of North America (Volume 32-5) (The Clinics: Internal Medicine, Volume 32-5) 1st Edition

This issue of Hematology/Oncology Clinics, edited by Drs. Jorge J. Castillo, Efstathios Kastritis, and Steven P. Treon, will focus on Waldenström Macroglobulinemia. Topics include, but are not limited to, Genomics; Epigenomics; Flow cytometry; Marrow microenvironment; Familial Waldenstrom; MYD88 L265P and other MYD88 mutations; CXCR4 and other recurrent mutations; Diagnosis and differential diagnosis; Criteria to treat and treatment goals; Alkylators; Monoclonal antibodies; Proteasome inhibitors; BTK inhibitors; Transplant; and Novel approaches.










Waldenström’s Macroglobulinemia 1st ed. 2017 Edition

This book sheds new light on clinical, biological and therapeutic data on the rare disease Waldenström’s Macroglobulinemia (WM) with the participation of widely-recognized experts, involved in this field. It represents the efforts of physicians, scientists and patients, all around the world, to better understand and cure this rare disease. Considerable advances in the diagnosis, treatment indications, response criteria, prognostic factors and treatment options have been made since Dr Jan Waldenström first reported this “new syndrome“ 70 years ago. Particularly instrumental in advancing of our understanding of WM have been the eight international workshops devoted to this disease. New, exciting molecular data have recently been reported, allowing us to revisit the oncogenic events leading to WM B-cell proliferation and to use newly available compounds targeting oncogenic pathways.


The Bing Center

Bing Center for Waldenstrom's

Dana-Farber Cancer Institute

Harvard Medical School

Administrative Contact

Christopher Patterson


Tel: (617)632-6285



Mailing Address

Dana-Farber Cancer Institute

450 Brookline Avenue


Boston, MA 02215